Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
RepliCel Retains Hybrid Financial for Investor Relations | ||
By: PR Newswire Association LLC. - 23 Sep 2017 | Back to overview list |
|
VANCOUVER, Sept. 22, 2017 /CNW/ - RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, is pleased to announce that it has retained Hybrid Financial Inc. ("Hybrid") to provide certain investor relations services (the "Services") to the Company, commencing September 26, 2017. Under the terms of Hybrid's engagement (the "Engagement"), RepliCel has agreed to pay Hybrid a monthly retainer of CAD$15,000 for an initial term of six months, with such retainer payable upon completion of RepliCel's next financing. Upon completion of the initial six-month term, RepliCel may extend the term of the Engagement on a month-to-month basis. The Engagement is subject to approval by the TSX Venture Exchange. Hybrid and/or its principals have an interest, directly or indirectly, in RepliCel securities. About RepliCel Life Sciences RepliCel is also developing a proprietary injection device (RCI-02) optimized for the administration of its products and licensable for use with other dermatology applications. Please visit http://replicel.com/ for additional information. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE RepliCel Life Sciences Inc. |
||
|
||
Copyright 2017 PR Newswire Association LLC. | Back to overview list |